3 active not recruiting, 2 completed, 2 terminated, 1 unknown. 5 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Immunic AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis IMU-838 tablets, Placebo matching IMU-838 tablets - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | Immunic AG | 1100 | 2022-01-12 | 2026-10-01 |
| IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer IMU-935 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Immunic AG | 18 | 2021-12-09 | 2024-01-17 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis IMU-838 tablets, Placebo matching IMU-838 tablets - Multiple Sclerosis | Phase 3 | Active not recruiting | Immunic AG | 1121 | 2021-11-18 | 2026-10-01 |
| Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis IMU-838, Placebo matching IMU-838 - Multiple Sclerosis | Phase 2 | Unknown | Immunic AG | 450 | 2021-09-30 | 2024-04-29 |
| IMU-838 and Oseltamivir in the Treatment of COVID-19 IMU-838, Oseltamivir - Covid 19 | Phase 2 | Completed | University Hospitals Coventry and Warwickshire NHS Trust | 38 | 2020-06-15 | 2023-08-22 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19) IMU-838, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Immunic AG | 234 | 2020-06-11 | 2024-11-13 |
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 2 | Active not recruiting | Immunic AG | 210 | 2019-01-28 | 2024-04-24 |
| Phase 2 Dose-finding IMU-838 for Ulcerative Colitis IMU-838, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Immunic AG | 263 | 2018-03-15 | 2024-03-05 |
Multiple Sclerosis (3) · COVID-19 (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Colitis, Ulcerative (1) · Multiple Sclerosis, Chronic Progressive (1)
Oseltamivir (1) · Tablets (1)
Bulgaria (5) · Poland (5) · Ukraine (5) · Germany (4) · Romania (4) · United Kingdom (4) · United States (4) · North Macedonia (3) · Russia (3) · Serbia (3) · Albania (2) · Bosnia and Herzegovina (2) · Czechia (2) · Georgia (2) · India (2)
Robert J. Fox, MD (3) · Andreas Muehler (2) · J. B., MD (1)
PMID 35698927, PMID 36242741, PMID 36396307, PMID 38662979, PMID 39791563, PMID 41933619
2017 (1), 2018 (1)